Floatz logo

Pembrolizumab

Advanced or Metastatic Solid Tumors

Hanmi Pharmaceutical Company Limitedmonoclonal_antibodyPhase 1/2Active
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
73/ 100

Competitive context

61 Active assets in the Advanced or Metastatic Solid Tumors cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Beijing Biotech
Phase 1/2B
Epirubicin
Hanmi Pharmaceutical Company Limited
Phase 1/2B
Eloxatin
ASLAN Pharmaceuticals
Phase 1/2CCC
Capecitabine
ASLAN Pharmaceuticals
Phase 1/2CCC
Carboplatin
NextCure, Inc.
Phase 1/2CCC

View all 50 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →